Journal
ANNUAL REVIEW OF VIROLOGY, VOL 8
Volume 8, Issue -, Pages 491-514Publisher
ANNUAL REVIEWS
DOI: 10.1146/annurev-virology-091919-103029
Keywords
HIV-1 latency; latency reversing agents; viral reservoirs; shock and kill strategy; combinatory treatments
Categories
Funding
- Belgian National Fund for Scientific Research (FRS-FNRS, Belgium)
- European Union's Horizon 2020 research and innovation program [691119-EU4HIVCURE-H2020-MSCA-RISE-2015]
- Fondation Roi Baudouin
- NEAT (European AIDS Treatment Network) program
- Internationale Brachet Stiftung
- ViiV Healthcare
- Walloon Region (Fonds de Maturation)
- Les Amis des Instituts Pasteur a Bruxelles
- University of Brussels (Action de Recherche Concertee grant)
Ask authors/readers for more resources
cART effectively reduces HIV-1 replication but cannot cure the infection due to the persistence of stable HIV-1-infected cellular reservoirs, leading to viral rebound upon cART interruption. The shock and kill strategy aims to reactivate latent viral gene expression and eliminate infected cells to reduce the size of the HIV-1 reservoir. Different classes of latency reversing agents (LRAs) have been studied to improve reactivation of viral gene expression, and combining multiple LRAs simultaneously or sequentially may optimize the shock strategy.
Combinatory antiretroviral therapy (cART) reduces human immunodeficiency virus type 1 (HIV-1) replication but is not curative because cART interruption almost invariably leads to a rapid rebound of viremia due to the persistence of stable HIV-1-infected cellular reservoirs. These reservoirs are mainly composed of CD4(+) T cells harboring replication-competent latent proviruses. A broadly explored approach to reduce the HIV-1 reservoir size, the shock and kill strategy, consists of reactivating HIV-1 gene expression from the latently infected cellular reservoirs (the shock), followed by killing of the virus-producing infected cells (the kill). Based on improved understanding of the multiple molecular mechanisms controlling HIV-1 latency, distinct classes of latency reversing agents (LRAs) have been studied for their efficiency to reactivate viral gene expression in in vitro and ex vivo cell models. Here, we provide an up-to-date review of these different mechanistic classes of LRAs and discuss optimizations of the shock strategy by combining several LRAs simultaneously or sequentially.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available